About
Erchonia: four decades of putting laser therapy through clinical trials
Erchonia has built its reputation on doing the harder thing: taking low-level laser devices through randomised, blinded, placebo-controlled trials rather than marketing around the absence of them.
The company
Evidence as a business model
Erchonia holds more than 20 FDA market clearances across body contouring, dermatology, podiatry and pain management — each supported by clinical data rather than substantial-equivalence claims alone.
The Emerald Laser is the culmination of that approach: the first and only laser cleared by the FDA for overall body circumference reduction in patients with a BMI up to 40, supported by a multi-site randomised, double-blind, placebo-controlled trial.
In Australia and New Zealand the range is supplied and supported by RehaCare International — Australian & New Zealand distributor for Erchonia, with local clinical training, protocol support and provider certification.
0+
Years of Erchonia laser innovation
0+
FDA market clearances across the range
0 min
Typical Emerald session length
0
Days of downtime required
Principles
How we work
Claim only what's cleared
Marketing language is bounded by regulatory clearance and published data.
Train before we supply
Every provider completes structured training before treating patients.
Support the practice
Protocols, documentation templates and patient materials come with the device.
Local clinical presence
ANZ-based clinical education, service and support — not offshore ticketing.
Experience the Erchonia range in your clinic
Book a private demonstration with the Erchonia Lasers Australia team, or find your nearest treating clinic.